Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Consolidated Diluted EPS Stands At $-3.9588

0

For the period ended 2015-12-31, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) delivered annual basic consolidated EPS of $-3.9588. In terms of quarterly performance, the basic consolidated EPS was $-3.9588 for the quarter ended 2015-12-31.

What about EPS from continuing operations?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) produced $-3.9588 in basic EPS from continuing operations for the annual period ended 2015-12-31. For the quarter, basic EPS from continuing operations was $-3.9588 for the three-month period ended 2015-12-31.

how much did parent contribute in EPS?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) received basic EPS boost of $-3.9588 from its parent company for the annual period ended 2015-12-31. For quarterly metrics, basic EPS contribution from the parent company was $-3.9588 for the three-month period ended 2015-12-31.

Basic net EPS

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) posted basic net EPS of $-3.96 for the annual period ended 2015-12-31. On quarterly basis, the basic net EPS for the quarter ended 2015-12-31 was $-3.96.

Consolidated diluted EPS

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) produced annual consolidated diluted EPS of $-3.9588 for the period ended 2015-12-31. But consolidated diluted EPS stood at $-3.9588 for the quarter ended 2015-12-31.

Basic diluted EPS

Basic diluted EPS of $-3.9588 came from continuing operation for the annual period ended 2015-12-31. In terms of quarterly performance, diluted EPS from continuing operations was $-3.9588 for the quarter ended 2015-12-31.

Net diluted EPS

The company posted net diluted EPS of $-3.96 for the annual period ended 2015-12-31. Coming to the quarter, it posted net diluted EPS of $-3.96 for the three-month period ended 2015-12-31.

Diluted EPS from parent

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) received diluted EPS boost of $-3.9588 from the parent company for the annual period ended 2015-12-31. For the quarter, diluted EPS from the parent was $-3.9588 for the quarter ended 2015-12-31.

For the annual period ended 2015-12-31, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) produced net basic EPS of $-3.96. On quarterly basis, it posted basic net EPS of $-3.96, which was for the three-month period ended 2015-12-31.

The annual average of the company’s basic shares outstanding was 36.783 for the period ended 2015-12-31. The quarterly average of basic shares outstanding was 36.783 for the quarter ended 2015-12-31.

The company had diluted shares outstanding of 36.783 for the annual period ended 2015-12-31 and 36.783 for the quarterly period ended 2015-12-31.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 5 times, 1 visits today)